Literature DB >> 22875593

Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus.

Dana Cechova1, Michaela Novakova, Karel Mikulik, Olga Novotna, Jaroslav Julak, Peter Zanvit, Ludmila Prokesova.   

Abstract

Mucosal immunization with non-living antigens usually requires the use of an adjuvant. The adjuvant activity of Bacillus firmus in the mucosal immunization of mice was described by our laboratory previously. In the present study, subcellular localization of B. firmus activities was followed. After mechanical disintegration, subcellular components of bacterium were fractionated by differential centrifugation and salting out. Bacterial cell walls, cytoplasmic membrane fraction, soluble cytoplasmic proteins, and ribosomal fractions were isolated. Their effect on the mouse immune system was studied. Lymphocyte proliferation and immunoglobulin formation in vitro were stimulated by bacterial cell wall (BCW), cytoplasmic membrane (CMF), and ribosomal fractions. BCW and CMF increased antibody formation after intratracheal immunization of mice with influenza A and B viruses, and increased protection against subsequent infection with influenza virus. The BCW fraction even induced intersubtypic cross-protection: Mice immunized with A/California/7/04 (H3N2) + BCW were resistant to the infection by the highly pathogenic A/PR/8/34 (H1N1) virus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875593     DOI: 10.1007/s12223-012-0181-y

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  41 in total

1.  Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.

Authors:  Maarten L van Roosmalen; Rolf Kanninga; Mohamed El Khattabi; Jolanda Neef; Sandrine Audouy; Tjibbe Bosma; Anneke Kuipers; Eduard Post; Anton Steen; Jan Kok; Girbe Buist; Oscar P Kuipers; George Robillard; Kees Leenhouts
Journal:  Methods       Date:  2006-02       Impact factor: 3.608

Review 2.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

3.  Immunostimulatory DNA sequences influence the course of adjuvant arthritis.

Authors:  Arash Ronaghy; Berent J Prakken; Kenji Takabayashi; Gary S Firestein; David Boyle; Nathan J Zvailfler; Sarah T A Roord; Salvatore Albani; Dennis A Carson; Eyal Raz
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A.

Authors:  Peter Zanvit; Aleš Tichopád; Martina Havlíčková; Olga Novotná; Marie Jirkovská; Katarína Kološtová; Dana Cechová; Jaroslav Julák; Ivan Sterzl; Ludmila Prokešová
Journal:  Immunol Lett       Date:  2010-08-13       Impact factor: 3.685

Review 5.  Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.

Authors:  N Lycke; M Bemark
Journal:  Mucosal Immunol       Date:  2010-09-15       Impact factor: 7.313

6.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

7.  A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation.

Authors:  Kenji Sugimoto; Mutsuhiro Ohata; Jun Miyoshi; Hiroyoshi Ishizaki; Naotake Tsuboi; Akio Masuda; Yasunobu Yoshikai; Masaya Takamoto; Kazuo Sugane; Seiichi Matsuo; Yasuhiro Shimada; Tetsuya Matsuguchi
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

Review 8.  Improvement of inactivated influenza virus vaccines.

Authors:  R B Couch; W A Keitel; T R Cate
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

9.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Authors:  Antoine Minne; Jamila Louahed; Sybille Mehauden; Benoît Baras; Jean-Christophe Renauld; Rita Vanbever
Journal:  Immunology       Date:  2007-05-22       Impact factor: 7.397

10.  Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.

Authors:  S Tamura; A Yamanaka; M Shimohara; T Tomita; K Komase; Y Tsuda; Y Suzuki; T Nagamine; K Kawahara; H Danbara
Journal:  Vaccine       Date:  1994-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.